trending Market Intelligence /marketintelligence/en/news-insights/trending/lcezt0j_8al77m4hkuacwa2 content esgSubNav
In This List

OncoMed names CEO

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


OncoMed names CEO

Redwood City, Calif.-based OncoMed Pharmaceuticals Inc. appointed John Lewicki as its CEO.

Lewicki, who will also join the company's board, will remain the company's president — a position he assumed in January.

Lewicki originally joined OncoMed in 2004 as senior vice president of research and development. He will lead the company as it advances its cancer treatments through clinical development.

He replaces Paul Hastings as CEO, who resigned at the beginning of 2018.